Universitair Ziekenhuis Gent — Sponsor Intelligence | 21 EU Trials

Filter these 21 trials by condition, phase, country and more.

Open in Search →

21 Registered trials

11 Recruiting

6 Completed trials

2 Countries active

49 Unique IMPs

100% Results reported

Phase III

Phase II

Phase IV

Phase I

Phase III: 5 Phase II: 4 Phase IV: 9 Phase I: 2 Phase I (Other): 1

Oversight events:

2 temporary halts across 2 trials

View oversight register →

100%

6 of 6 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Coronary artery disease 1 Peripheral spondyloarthritis 1 Non-small cell lung cancer metastatic 1

Top IMPs

CORIFOLLITROPIN ALFA 2 FLUDARABINE PHOSPHATE 2 FOLLITROPIN BETA 2 GANIRELIX 2 GOZETOTIDE ALF-18 2 ANTI-T LYMPHOCYTE IMMUNOGLOBULIN FOR HUMAN USE, RABBIT 1 AXICABTAGENE CILOLEUCEL 1 BREXUCABTAGENE AUTOLEUCEL 1 CARBOPLATIN 1 CEMIPLIMAB 1 CHORIOGONADOTROPIN ALFA 1 CILTACABTAGENE AUTOLEUCEL 1

All trials

21 total

F-18 PSMA-11 PET for Imaging and Staging of Hepatocellular carcinoma with Evaluation of Survival Pending

2023-508709-26-00 Phase II 1 country GOZETOTIDE ALF-18
A phase 1b study of an autologous dendritic cell immunotherapy in combination with anti-programmed death-1 treatment in patients with metast… Pending

2025-521577-13-00 Phase I 1 country CARBOPLATIN; CEMIPLIMAB; CISPLATIN; MIDRIX-LUNG-001; MIDRIX-LUNG-002; PACLITAXEL…
Fludarabine exposure in patients undergoing Fludarabine based lymphodepletion prior to CAR-T cell therapy Pending

2025-524278-40-00 Phase IV 1 country AXICABTAGENE CILOLEUCEL; BREXUCABTAGENE AUTOLEUCEL; CILTACABTAGENE AUTOLEUCEL; C…
A pHase III cluster randomIsed controlled, cross-over, non-inferiority Trial of a short course, High dose AntimicRobials vs conventional dos… Recruiting

2024-514730-21-00 Phase III 2 countries
Cumulative exposure to Fludarabine in patients undergoing reduced intensity allogeneic stem cell transplantation in Belgium Recruiting

2023-503723-26-00 Phase IV 1 country ANTI-T LYMPHOCYTE IMMUNOGLOBULIN FOR HUMAN USE, RABBIT; FLUDARABINE PHOSPHATE; M…
Early Model-Informed Precision Dosing of beta-lactam antibiotics in critically ill children: big solution for small people? Recruiting

2024-516447-12-00 Phase IV 1 country
PPOS (Progestin primed ovarian stimulation) and Corifollitropin alfa (CFA) cross-over study Recruiting

2023-506694-35-00 Phase IV 1 country CORIFOLLITROPIN ALFA; DESOGESTREL; FOLLITROPIN BETA; GANIRELIX; TRIPTORELIN ACET…
Proactive TDM versus standard use of biologics in psoriasis (HELIOS) Recruiting

2023-509637-39-00 Phase IV 1 country GUSELKUMAB; IXEKIZUMAB; SECUKINUMAB
Optimizing treatment strategy in axial spondyloarthritis by molecular imaging with Technetium-labeled certolizumab pegol. Recruiting

2023-505694-32-00 Phase III 1 country TECHNETIUM (99MTC) CERTOLIZUMAB PEGOL
Psilocybin for hospitalized patients with treatment-resistant depression Recruiting

2022-501857-35-00 Phase II 1 country DRY EXTRACT FROM PSILOCYBE CUBENSIS (15-25:1), EXTRACTION SOLVENT: METHANOL
[18F]AlF-PSMA-11 PET in advanced thyroid and head and neck carcinoma Recruiting

2022-503036-13-00 Phase II 1 country GOZETOTIDE ALF-18
COLchicine in BElgium in patients with coronary artery disease after Percutaneous Coronary Intervention Recruiting

2023-505028-74-00 Phase III 1 country COLCHICINE
Remifentanil for endotracheal intubation in neonates: a dose-finding trial. Recruiting

2022-501858-11-00 Phase III 1 country REMIFENTANIL; SODIUM CHLORIDE
A randomized comparison of one controlled ovarian stimulation with corifollitropin alfa (CFA) versus up to three modified natural cycles (MN… Recruiting

2023-509094-23-00 Phase IV 1 country CHORIOGONADOTROPIN ALFA; CORIFOLLITROPIN ALFA; FOLLITROPIN BETA; GANIRELIX
A randomized active-controlled trial for vulvovaGinal atRophy in breAst Cancer patients on Endocrine therapy (GRACE-trial) Ended

2024-510845-33-00 Phase IV 1 country ESTRIOL; ESTRIOL, LACTOBACILLUS ACIDOPHILUS, LYOPHILIZED; PRASTERONE
Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis from Gastrointestinal cancer: a phase I study. Ended

2023-509135-17-00 Phase I (Other) 1 country
SPondyloArthritis: inducing drug-free Remission by early TNF-Alpha bloCkade Under guidance of Single cell RNA sequencing and epigenetic prof… Ended

2023-510085-27-00 Phase III 1 country GOLIMUMAB; METHOTREXATE DISODIUM
Dosimetry of a novel amino acid PET tracer, [18F]FELP Halted

2022-501696-91-00 Phase I 1 country
Characterisation and intervention study in patients with long-term use of nasal decongestants. Ended

2024-516312-25-00 Phase IV 1 country
Stereotactic body radiotherapy with or without Darolutamide for OligoRecurrent prostate cancer: a randomized phase II trial (DART) Ended

2024-511140-37-00 Phase II 1 country DAROLUTAMIDE
Virological and immunological assessment in HIV positive participants on 2DR versus 3DR in a prospective randomized controlled switch trial. Ended

2024-515265-34-00 Phase IV 1 country EMTRICITABINE, TENOFOVIR ALAFENAMIDE, BICTEGRAVIR; LAMIVUDINE, DOLUTEGRAVIR SODI…

Showing 1–21 of 21 trials

← All sponsors A–Z